Systematic review: The prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 9, 2012, Pages 987-999

  Hakeem, A R ^a   Young, R S ^a   Marangoni, G ^a   Lodge, J P A ^a   Prasad, K R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PATIENT COUNSELING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENCE RISK; REVIEW; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875705928     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05060.x     Document Type: Review

References (88)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
2. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 5: 1080-6.
3. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence based decision. Liver Transpl 2003; 7: 700-2.
4. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609.
5. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
6. Altman DG. Systematic Reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-8.
7. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
8. Atkins D, Best D, Briss P, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
9. Hayden JA, Cote P, Bombardier C. Evaluation of the Quality of Prognosis Studies in Systematic Reviews. Ann Intern Med 2006; 144: 427-37.
10. Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-12.
11. Varona MA, Del Pino JM, Barrera M, et al. Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc 2009; 41: 1005-8.
12. Castroagudín JF, Molina E, Bustamante M, et al. Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience. Transplant Proc 2008; 40: 2975-7.
13. Boin IF, Pracucho EM, Rique MC, et al. Expanded Milan criteria on pathological examination after liver transplantation: analysis of preoperative data. Transplant Proc. 2008; 40(): 777-9.
14. Kondili LA, Lala A, Gunson B, et al. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol 2007; 33: 868-73.
15. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708-16.
16. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005; 11: 1265-72.
17. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497-503.
18. Leung JY, Zhu AX, Gordon FD, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004; 10: 1343-54.
19. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-8.
20. Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-62.
21. De Carlis L, Giacomoni A, Pirotta V, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 2003; 196: 887-97.
22. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) 2010; 12: 56-61.
23. Jang JW, You CR, Kim CW, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-23.
24. Compagnon P, Grandadam S, Lorho R, et al. Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy. Transplantation 2008; 86: 1068-76.
25. Park JW, Lee KW, Kim SJ, et al. Outcome of patients with recurrent hepatocellular carcinoma in liver transplantation. Transplant Proc 2006; 38: 2121-2.
26. Moya A, Berenguer M, Aguilera V, et al. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl 2002; 8: 1020-7.
27. Chen CL, Concejero AM. Liver transplantation for hepatocellular carcinoma in the world: the Taiwan experience. J Hepatobiliary Pancreat Sci 2010; 17: 555-8.
28. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-51.
29. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-32.
30. McPeake JR, O'Grady JG, Zaman S, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 1993; 18: 226-34.
31. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-25.
32. Saito H, Masuda T, Tada S, et al. Hepatocellular carcinoma in Keio affiliated hospitals-diagnosis, treatment, and prognosis of this disease. Keio J Med 2009; 58: 161-75.
33. Pascual S, Zapater P, Such J, et al. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 2006; 26: 673-9.
34. Shen BY, Li HW, Regimbeau JM, Belghiti J. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 401-5.
35. Herold C, Reck T, Fischler P, et al. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 2002; 22: 23-8.
36. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 1086-92.
37. Figueras J, Ibañez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-83.
38. Levi DM, Tzakis AG, Martin P, et al. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg 2010; 210: 727-34.
39. Fouzas I, Sotiropoulos GC, Sgourakis G, et al. Five-year survival after monotherapy for hepatocellular carcinoma in the setting of cirrhosis. Transplant Proc 2008; 40: 3204-5.
40. Wai CT, Lee YM, Wang SC, et al. Liver transplantation for hepatocellular carcinoma in Singapore. Singapore Med J 2006; 47: 584-7.
41. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, et al. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005; 18: 1498-503.
42. Barakat O, Wood RP, Ozaki CF, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010; 16: 289-99.
43. Coelho GR, Vasconcelos KF, Vasconcelos JB, et al. Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil. Transplant Proc 2009; 41: 1740-2.
44. El-Meteini M, Fayez A, Fathy M, et al. Living related liver transplantation for hepatocellular carcinoma in Egypt. Transplant Proc 2005; 37: 3141-3.
45. Xu X, Ke QH, Shao ZX, et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009; 54: 385-8.
46. Andorno E, Salizzoni M, Schieroni R, De Hemptinne B. Role of serum alphafetoprotein in pre- and post-orthotopic liver transplantation (OLT) for malignant disease. J Nucl Med Allied Sci 1989; 3(Suppl.): 132-4.
47. Ho MC, Wu YM, Hu RH, et al. Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc 2004; 36: 2291-2.
48. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-51.
49. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-8.
50. Shimoda M, Ghobrial RM, Carmody IC, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 2004; 10: 1478-86.
51. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998; 5: 29-34.
52. Shimada M, Yonemura Y, Ijichi H, et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gammacarboxy prothrombin value. Transplant Proc 2005; 37: 1177-9.
53. Zhou J, Fan J, Wu ZQ, et al. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China. Chin Med J (Engl) 2005; 118: 654-9.
54. Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240: 451-9.
55. Cescon M, Ravaioli M, Grazi GL, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; doi:10.1155/2010/904152.
56. Shin WY, Suh KS, Lee HW, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 678-84.
57. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-27.
58. Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195-202.
59. Zhang M, Li B, Yan LN, et al. Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol 2008; 14: 1280-5.
60. Han K, Tzimas GN, Barkun JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45.
61. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-37.
62. Sotiropoulos GC, Lang H, Sgourakis G, et al. Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned. Dig Dis Sci 2009; 54: 377-84.
63. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alphafetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-9.
64. Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum afetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011; 146: 26-33.
65. Wang ZX, Song SH, Teng F, et al. A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma. Clin Transplant 2010; 24: 752-7.
66. Xiao L, Fu ZR, Ding GS, et al. Liver transplantation for hepatitis B virusrelated hepatocellular carcinoma: one center's experience in China. Transplant Proc 2009; 41: 1717-21.
67. Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-71.
68. Lao OB, Weissman J, Perkins JD. Pretransplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant 2009; 23: 874-81.
69. Zou WL, Zang YJ, Chen XG, Shen ZY. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 145-51.
70. Adler M, De Pauw F, Vereerstraeten P, et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008; 14: 526-33.
71. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2009; 15: 574-80.
72. Pérez-Saborido B, de los Galanes SJ, Menéu-Díaz JC, et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. Transplant Proc 2007; 39: 2304-7.
73. Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007; 13(Suppl. 2): S48-54.
74. Sotiropoulos GC, Lang H, Nadalin S, et al. Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 2007; 205: 661-75.
75. Oxford centre for Evidence-based Medicine- Levels of Evidence. Available at: http://www.cebm.net. Accessed February 21, 2011.
76. Koike Y, Shiratori Y, Sato S, et al. Desgamma- carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
77. Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gammacarboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544-9.
78. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1963; 1: 174-80.
79. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009; 100: 1219-29.
80. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700-7.
81. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127(Suppl. 1): S108-12.
82. Snowberger N, Chinnakotla S, Lepe RM, et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007; 26: 1187-94.
83. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-76.
84. Tan CK, Gores GJ, Steers JL, et al. Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. Mayo Clin Proc 1994; 69: 509-14.
85. Oya H, Sato Y, Yamamoto S, et al. Comparison between human-telomerase reverse transcriptase mRNA and alphafetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. Transplant Proc 2006; 38: 3636-9.
86. Marubashi S, Dono K, Sugita Y, et al. Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2006; 38: 3640-2.
87. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-9.
88. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-7.